Renishaw Completes Clinical Trial Extension Study of Neuroinfuse Drug Delivery System to Treat Parkinson’s Disease
Global engineering technologies company, Renishaw, has concluded the extension component of its phase 1-2 clinical study, carried out jointly with pharmaceuticals expert Herantis Pharma, which investigated the safety and performance of its neuroinfuse drug delivery device and cerebral dopamine neurotrophic factor (CDNF), as a treatment for Parkinson’s disease.
